Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsNov. 13, 2025 7:51 PM ETFitLife Brands, Inc. (FTLF) StockFTLFSA Transcripts156.79K FollowersCommentsFitLife Brands, Inc. (FTLF) Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsDayton Judd - Chairman & CEOConference Call ParticipantsRyan Meyers - Lake Street Capital Markets, LLC, Research DivisionSean McGowan - ROTH Capital Partners, LLC, Research DivisionSamir Patel - Askeladden Capital Management LLCPresentationOperatorGood afternoon, and welcome to the FitLife Brands Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Dan Judd, CEO of FitLife Brands. Dan, the floor is yours.Dayton JuddChairman & CEOThank you, Tom. I would like to welcome everyone to FitLife's Third Quarter 2025 Earnings Call. We appreciate you taking the time to join us this afternoon. Joining me on the call is FitLife's CFO, Jakob York; and FitLife's EVP, Ryan Hansen. As we typically do, I'll provide some opening commentary to get us started, and then we'll open the call up for Q&A.Before jumping into the numbers, let me begin by saying how excited we are about our previously announced acquisition of Irwin Naturals, which closed on August 8, 2025. FitLife's financial results for the third quarter of 2025 include Irwin's performance for the 53-day period from August 9 through September 30.In addition, beginning with this quarter, the results of MRC are now reported as part of Legacy FitLife. However, we will continue to provide more detailed disclosure about MRC when it makes sense to do so.For the company overall, for the third quarter of 2025, total revenue increased 47% year-over-year to $23.5 million. Revenue from Irwin accounted for $6.8 million of the $7.5 million revenue increase during the quarter. This means that our other brands collectively delivered $0.7 million of organic growth during the quarter. MRC declined, but Legacy FitLife, excluding MRC, delivered 8% organic growth during the quarter, and MusclePharmRead more current FTLF analysis and newsView all earnings call transcriptsCommentsRecommended For YouTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.